Mitotech S.A. is a Luxembourg-based biotech company focused on developing innovative drugs for age-related disorders. Their drug portfolio includes an ophthalmic drug and a systemic drug, both containing SkQ1, a highly efficient mitochondria-targeted antioxidant. With a team of scientific experts, clinical drug development professionals, and business managers, Mitotech aims to turn biological research into pharmaceutical products that protect against cellular oxidative stress. Their mission is to deliver medications with a novel mechanism of action to millions of patients worldwide, leveraging breakthroughs in delivering antioxidants into mitochondria. The company is backed by investors RUSNANO and Rostok Group.